Bard Financial Services Inc. Acquires 2,000 Shares of Kenvue Inc. (NYSE:KVUE)

Bard Financial Services Inc. grew its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 1.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 108,790 shares of the company’s stock after purchasing an additional 2,000 shares during the quarter. Bard Financial Services Inc.’s holdings in Kenvue were worth $2,323,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in KVUE. Commonwealth Equity Services LLC boosted its stake in Kenvue by 7.1% in the second quarter. Commonwealth Equity Services LLC now owns 278,747 shares of the company’s stock valued at $5,068,000 after acquiring an additional 18,506 shares during the last quarter. National Bank of Canada FI grew its holdings in Kenvue by 23.8% during the second quarter. National Bank of Canada FI now owns 417,999 shares of the company’s stock valued at $7,527,000 after purchasing an additional 80,272 shares during the period. Victory Capital Management Inc. increased its position in Kenvue by 54.9% in the second quarter. Victory Capital Management Inc. now owns 799,225 shares of the company’s stock worth $14,530,000 after buying an additional 283,383 shares during the last quarter. Arizona State Retirement System raised its stake in shares of Kenvue by 12.2% in the second quarter. Arizona State Retirement System now owns 555,048 shares of the company’s stock valued at $10,091,000 after buying an additional 60,463 shares during the period. Finally, Candriam S.C.A. lifted its position in shares of Kenvue by 20.8% during the 2nd quarter. Candriam S.C.A. now owns 85,878 shares of the company’s stock valued at $1,561,000 after buying an additional 14,784 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

KVUE has been the topic of a number of research reports. Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $21.00 to $26.00 in a research note on Monday. Barclays upgraded shares of Kenvue to a “hold” rating in a research note on Thursday, December 12th. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and reduced their price objective for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Royal Bank of Canada upgraded Kenvue from a “hold” rating to a “moderate buy” rating in a research report on Monday, December 9th. Finally, Jefferies Financial Group initiated coverage on Kenvue in a research report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 price target for the company. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $23.09.

Kenvue Price Performance

Kenvue stock traded up $0.02 during midday trading on Monday, hitting $21.22. 4,009,091 shares of the company’s stock were exchanged, compared to its average volume of 6,003,324. The stock has a 50-day moving average price of $22.81 and a two-hundred day moving average price of $21.51. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The company has a market cap of $40.68 billion, a P/E ratio of 38.58, a PEG ratio of 2.02 and a beta of 1.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.01. The company had revenue of $3.90 billion for the quarter, compared to analysts’ expectations of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. Kenvue’s revenue for the quarter was down .4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.31 earnings per share. On average, equities research analysts forecast that Kenvue Inc. will post 1.07 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th were given a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.86%. The ex-dividend date of this dividend was Wednesday, November 13th. Kenvue’s dividend payout ratio (DPR) is currently 149.09%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.